Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06779851 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Bright Peak Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 7
- Study locations
NCT06779851: Active Phase 1 study of Advanced Solid Tumors, sponsored by Bright Peak Therapeutics.
NCT06779851 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Bright Peak Therapeutics. The registered enrollment target is 100 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06779851, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Bright Peak Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.
Primary Outcome
The MTD will be the highest tested dose of BPT567 at which protocol specified number of patients experience DLT or the MAD, highest administered dose in the absence of DLTs
Conditions Studied
Interventions
- DRUG BPT567
Study Locations (7)
Arizona
- Honor Health Research Institute - Scottsdale
Michigan
- Start Midwest - Grand Rapids
New Jersey
- Hackensack Meridian John Theurer Cancer Center - Hackensack
North Carolina
- Carolina BioOncology Institute - Huntersville
Oregon
- Providence Cancer Institute - Portland
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What the registry record for NCT06779851 still lists
NCT06779851 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which BPT567 is the first listed.
NCT06779851 lists 7 locations in 7 states (Arizona, Michigan, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06779851 about?
NCT06779851 is a clinical study titled "A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors". This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced ...
What is the current status of trial NCT06779851?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-10-15. Estimated completion is 2028-12-31.
What conditions does trial NCT06779851 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06779851?
The interventions under investigation include: BPT567 (DRUG).
Who is sponsoring clinical trial NCT06779851?
This trial is sponsored by Bright Peak Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06779851 being conducted?
This trial has 7 study locations across Arizona, Michigan, New Jersey, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06779851's enrollment target sits among peer trials
100 80th of 144 higher than 63 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI